Do patients live longer on Kisqali plus letrozole vs letrozole alone (MONALEESA-2)?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)
How long did Kisqali plus letrozole delay progression vs letrozole alone (MONALEESA-2)?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)
Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 19 of the Prescribing Information.
Who was studied in the Kisqali MONALEESA-2 trial?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)
Do patients live longer on Kisqali plus fulvestrant vs fulvestrant alone (MONALEESA-3)?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)
How long did Kisqali plus fulvestrant delay progression vs fulvestrant alone (MONALEESA-3)?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)
Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 21 of the Prescribing Information, whose comparator arm is placebo plus fulvestrant.
Do premenopausal women live longer on Kisqali plus an NSAI and goserelin (MONALEESA-7)?
Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)
How long did Kisqali delay progression in premenopausal women (MONALEESA-7)?
Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)
Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 20 of the Prescribing Information (MONALEESA-7 NSAI subgroup), which gives the medians in months.
How long did Kisqali delay chemotherapy in premenopausal women (MONALEESA-7)?
Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)
On the page, select: Does reducing the KISQALI dose affect treatment effectiveness for patients with metastatic breast cancer?
Subgroup results
What was Kisqali overall survival by age group (pooled post hoc MONALEESA analysis)?
Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7
What was overall survival with Kisqali plus fulvestrant in visceral metastases (MONALEESA-3)?
Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)
Note: The page presents this subgroup analysis for first- and second-line (1L/2L) postmenopausal patients from MONALEESA-3.
Comparative studies
How did Kisqali compare with chemotherapy in RIGHT Choice patients without visceral crisis?
Applies to Pre- and perimenopausal women with aggressive HR-positive, HER2-negative advanced or metastatic breast cancer, first-line, with an aromatase inhibitor and goserelin (RIGHT Choice)